Silexion Therapeutics Corp 8-K

What Happened

• Silexion Therapeutics Corp. (SLXN) filed a Form 8-K on May 18, 2026 to report its results of operations and financial condition for the quarter ended March 31, 2026.
• The company furnished a press release dated May 18, 2026 titled “Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update” as Exhibit 99.1, which is incorporated by reference into the filing (Item 2.02 and Item 9.01).

Key Details

• Filing date: May 18, 2026 (Form 8-K).
• Reporting period: quarter ended March 31, 2026.
• Press release furnished as Exhibit 99.1 and incorporated by reference.
• Items reported on the Form 8-K: 2.02 (Results of operations and financial condition) and 9.01 (Financial statements and exhibits).

Why It Matters

• The 8-K makes Silexion’s quarterly results and any accompanying business update publicly available; investors should review the Exhibit 99.1 press release for specific earnings, revenue, cash position, and operational details.
• Quarterly disclosures like this can affect short-term stock reaction and help investors evaluate the company’s financial health and progress on its business plans.